[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-338008-en":59,"doc-seo-338008-105":98},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":72,"language":73,"language_code":74,"site_id":75,"html_lang":74,"table_of_contents":76,"faqs":77,"seo_title":78,"seo_description":66,"update_tm":79,"read_time":36,"preview_page_count":19,"preview_urls":80},338008,8796095461564,"Liam","https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer - Received 28 August 2023","Rosiglitazone and trametinib show strong anti-tumor effects in a mouse model of muscle-invasive bladder cancer, particularly in basal/squamous (BASQ) tumors where Pparg expression is low or undetectable. Rosiglitazone reduces proliferation, while rosiglitazone combined with trametinib induces apoptosis and reduces tumor volume by 91% after one month. The treatment also shifts tumor differentiation from BASQ toward luminal programs, linked to retinoid signaling, suggesting potential clinical activity in BASQ patients.","Article [https://doi.org/10.1038/s41467-024-50678-2](https://doi.org/10.1038/s41467-024-50678-2)  \nRosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer  \nReceived: 28 August 2023  \n\n| Accepted: 18 July 2024 |\n| --- |\n| |\n| Check for updates |\n\nSakina A. Plumber 1,11, Tiffany Tate1,8,11, Hikmat Al-Ahmadie 2, Xiao Chen3,9, Woonyoung Choi 4, Merve Basar3,10, Chao Lu 3, Aaron Viny 5,  \nEkatherina Batourina1, Jiaqi Li1, Kristjan Gretarsson 3, Besmira Alija5,  \nAndrei Molotkov1, Gregory Wiessner1, Byron Hing Lung Lee6, James McKiernan1, David J. McConkey 4, Colin Dinney6, Bogdan Czerniak 7 &  \nCathy Lee Mendelsohn 1   \nMuscle invasive bladder cancers (BCs) can be divided into 2 major subgroupsbasal/squamous (BASQ) tumors and luminal tumors. Since Pparg has low or undetectable expression in BASQ tumors, we tested the effects of rosiglitazone, Pparg agonist, in a mouse model ofBASQ BC. We ﬁnd that rosiglitazone reduces proliferation while treatment with rosiglitazone plus trametinib, a MEK inhibitor, induces apoptosis and reduces tumor volume by 91% after 1 month. Rosiglitazone and trametinib also induce a shift from BASQ to luminal differentiation in tumors, which our analysis suggests is mediated by retinoid signaling, a pathway known to drive the luminal differentiation program. Our data suggest that rosiglitazone, trametinib, and retinoids, which are all FDA approved, may be clinically active in BASQ tumors in patients.  \nUrothelial carcinoma of the bladder (bladder cancer; BC) is currently the 6th most common form of cancer in the United States with about 81,000 new cases and 17,000 deaths per year. It occurs three times more frequently in men than in women1–3, but women tend to have more aggressive disease4. Most cases of BC (70%) present as nonmuscle invasive bladder cancer (NMIBC) that includes patients with stage Ta and T1 tumors as well as carcinoma in situ. All NMIBCs are treated with complete transurethral resection, and patients with highrisk disease are also treated with adjuvant intravesical BCG. However, 50–70% ofpatients experience recurrence and up to 20% ofhigh-grade NMIBCs progress to muscle invasive bladder cancer [MIBC2]. MIBC is associated with a 50% ﬁve-year survival rate, and metastatic progression almost always leads to death5,6.  \nNeoadjuvant cisplatin-based chemotherapy followed by deﬁnitive surgery (radical cystectomy) has been the preferred treatment for MIBC since the early 2000s7–9, although radiation-based trimodal therapy (TMT) is equally effective in well-selected patients10. Immunecheckpoint inhibitors (ICIs) such as atezolizumab and pembrolizumabare active in approximately 20% of patients with advanced and metastatic disease11–13, and novel combinations of ICIs and antibody-drug conjugates are displaying even stronger activity, although the durability of this beneﬁt is still unclear. In contrast to basal/squamous (BASQ) tumors, many luminal papillary (LP) tumors are poorly inﬁltrated with immune cells, and this subset of tumors has a lower response rate to immune checkpoint inhibitors2,12,14–17. Overall, there is still a great need to identify new avenues for treatment of BC.  \n1Department of Urology, Columbia University Irving Medical Center, New York, NY, USA. 2Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3Department of Genetics&Development, Columbia University Irving Medical Center, New York, NY, USA. 4Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA. 5Department of Medicine, Division of Hematology & Oncology, Columbia University Irving Medical Center, New York, NY, USA. 6Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 7Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 8Present address: Generation Bio, Cambridge, MA, USA. 9Present address: Marine College, Shandong University, Weihai, China. 10Present address: Harva","cbCaibIxmO2lL09H","https://ap.wps.com/l/cbCaibIxmO2lL09H","pdf",3873824,16,"English","en",105,"# Background\n## Bladder cancer subtypes and unmet needs\n# Mechanistic rationale\n## Role of Pparg in tumor subtype\n# Experimental approach\n## Mouse BASQ model and treatment dosing\n# Findings\n## Proliferation, apoptosis, tumor shrinkage\n## Differentiation shift and signaling linkage","[{\"question\":\"Why target Pparg in basal/squamous bladder cancer?\",\"answer\":\"BASQ tumors show low or undetectable Pparg expression, while luminal tumors more often exhibit Pparg-dependent transcriptional activation. This suggests subtype-specific vulnerability that can be exploited by Pparg agonists.\"},{\"question\":\"What is the anti-tumor effect of rosiglitazone and trametinib in the mouse model?\",\"answer\":\"Rosiglitazone alone reduces tumor proliferation. The combination of rosiglitazone plus trametinib induces apoptosis within 7 days and decreases tumor volume by 91% after one month.\"},{\"question\":\"How does the combination treatment affect tumor differentiation?\",\"answer\":\"The data indicate a shift from BASQ to luminal differentiation in tumors. Analysis suggests this is mediated by retinoid signaling, a pathway associated with the luminal differentiation program.\"}]","Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer - Received 28 August 2023 | PDF",1790021548,[81,85,89,94],{"page_no":8,"url":82,"width":83,"height":84},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c3c2c8fd316e5274883eefac72d22f2f.webp",983,1305,{"page_no":14,"url":86,"width":87,"height":88},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b05eb772e2b38f569c726d29fe786b8e.webp",982,1304,{"page_no":90,"url":91,"width":92,"height":93},3,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c24fcc6ba10e8f2ae50dc24a8b5592f2.webp",981,1303,{"page_no":19,"url":95,"width":96,"height":97},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0a2df915b6e5e24a70da72cca53ec230.webp",980,1301,{"code":4,"msg":99,"data":100},"ok",{"site_id":75,"language":74,"slug":101,"title":65,"keywords":102,"description":66,"schema_data":103,"social_meta":156,"head_meta":158,"extra_data":160,"updated_unix":161},"rosiglitazone-and-trametinib-exhibit-potent-anti-tumor-activity-in-a-mouse-model-of-muscle-invasive-bladder-cancer-received-28-august-2023","",{"@graph":104,"@context":155},[105,118,138],{"@type":106,"itemListElement":107},"BreadcrumbList",[108,112,114,116],{"item":109,"name":110,"@type":111,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":113,"name":9,"@type":111,"position":14},"https://docshare.wps.com/document/",{"item":115,"name":40,"@type":111,"position":90},"https://docshare.wps.com/document/research-report/",{"item":117,"name":65,"@type":111,"position":19},"https://docshare.wps.com/document/rosiglitazone-and-trametinib-exhibit-potent-anti-tumor-activity-in-a-mouse-model-of-muscle-invasive-bladder-cancer-received-28-august-2023/338008/",{"url":117,"name":65,"@type":119,"image":120,"author":125,"headline":65,"publisher":127,"fileFormat":130,"inLanguage":74,"description":66,"dateModified":131,"datePublished":132,"encodingFormat":130,"isAccessibleForFree":133,"interactionStatistic":134},"DigitalDocument",{"url":121,"@type":122,"width":123,"height":124},"https://docshare.wps.com/thumbnails/rosiglitazone-and-trametinib-exhibit-potent-anti-tumor-activity-in-a-mouse-model-of-muscle-invasive-bladder-cancer-received-28-august-2023/338008.png","ImageObject",300,407,{"name":63,"@type":126},"Person",{"url":109,"name":128,"@type":129},"DocShare","Organization","application/pdf","2026-11-10","2026-09-21",true,{"@type":135,"interactionType":136,"userInteractionCount":34},"InteractionCounter",{"@type":137},"ViewAction",{"@type":139,"mainEntity":140},"FAQPage",[141,147,151],{"name":142,"@type":143,"acceptedAnswer":144},"Why target Pparg in basal/squamous bladder cancer?","Question",{"text":145,"@type":146},"BASQ tumors show low or undetectable Pparg expression, while luminal tumors more often exhibit Pparg-dependent transcriptional activation. This suggests subtype-specific vulnerability that can be exploited by Pparg agonists.","Answer",{"name":148,"@type":143,"acceptedAnswer":149},"What is the anti-tumor effect of rosiglitazone and trametinib in the mouse model?",{"text":150,"@type":146},"Rosiglitazone alone reduces tumor proliferation. The combination of rosiglitazone plus trametinib induces apoptosis within 7 days and decreases tumor volume by 91% after one month.",{"name":152,"@type":143,"acceptedAnswer":153},"How does the combination treatment affect tumor differentiation?",{"text":154,"@type":146},"The data indicate a shift from BASQ to luminal differentiation in tumors. Analysis suggests this is mediated by retinoid signaling, a pathway associated with the luminal differentiation program.","https://schema.org",{"og:url":117,"og:type":157,"og:title":65,"og:site_name":128,"og:description":66},"article",{"robots":159,"canonical":117},"index,follow",{"doc_id":61,"site_id":75},1790541039]